

|  |  |
| --- | --- |
| **Examination question paper:** | **July 2025** |

|  |  |
| --- | --- |
| **Module code:**  **Component number:** | **BM7048**  **002** |
| **Module title:** | **Cancer Immunotherapy** |
| **Module leader:** | **Prof. Jameel M. Inal** |

|  |  |
| --- | --- |
| **Date:** | **July 2025** |
| **Duration:** | **1 Hour 30 Minutes** |

|  |  |
| --- | --- |
| **Exam type:** | **Seen, Closed** |
| **Materials supplied:** | **None** |
| **Materials permitted:** | **None** |
| **Warning:** | **Candidates are warned that possession of unauthorised materials in an examination is a serious assessment offence.** |

|  |  |
| --- | --- |
| **Instructions to candidates:** | **Candidates will be required to answer all THREE questions** |
|  |  |
|  |  |
|  | **Do not turn page over until instructed** |

© London Metropolitan University

**Answer all THREE questions**

**Q1. In relation to antigen-specific T cell therapy explain in detail some of the problems that engineered T cells encounter in the immunosuppressive tumour microenvironment.**

**20 marks**

**Q2. With respect to DNA vaccination, explain some of the extracellular and intracellular barriers to delivery of DNA. Also explain how the use of a ‘nanoparticulate cancer vaccine,’ (so-called nanogel) may constitute a successful delivery system**.

**20 marks**

**Q3. David Lyden’s seminal work reveals how exosomes derived from primary tumours may set up a pre-metastatic niche. With reference to this, discuss recent findings on the tumour microenvironment and cancer metastasis.**

**20 marks**